Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Orentas Website

Rimas J. Orentas, Ph.D.

Selected Publications

1)  Kroesen M, Nierkens S, Ansems M, Wassink M, Orentas RJ, Boon L, den Brok MH, Hoogerbrugge PM, Adema GJ.
A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
Int. J. Cancer. 134: 1335-45, 2014.
[Journal]
2)  Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ.
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Blood. 121: 1165-74, 2013.
[Journal]
3)  Zhang H, Maric I, DiPrima MJ, Khan J, Orentas RJ, Kaplan RN, Mackall CL.
Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer.
Blood. 122: 1105-13, 2013.
[Journal]
4)  Long AH, Haso WM, Orentas RJ.
Lessons learned from a highly-active CD22-specific chimeric antigen receptor.
Oncoimmunology. 2: e23621, 2013.
[Journal]
5)  Orentas RJ.
Reading the tea leaves of tumor-mediated immunosuppression.
Clin. Cancer Res. 19: 955-7, 2013.
[Journal]
6)  Stauffer JK, Orentas RJ, Lincoln E, Khan T, Salcedo R, Hixon JA, Back TC, Wei JS, Patidar R, Song Y, Hurd L, Tsokos M, Lai EW, Eisenhofer G, Weiss W, Khan J, Wigginton JM.
High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery.
Cancer Invest. 30: 343-63, 2012.
[Journal]
7)  Orentas RJ, Yang JJ, Wen X, Wei JS, Mackall CL, Khan J.
Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers.
Front Oncol. 2: 194, 2012.
[Journal]
8)  Orentas RJ, Lee DW, Mackall C.
Immunotherapy targets in pediatric cancer.
Front Oncol. 2: 3, 2012.
[Journal]
9)  Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA.
The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.
Clin. Cancer Res. 18: 2780-90, 2012.
[Journal]
10)  Zheng J, Orentas R, Yan X, Liu H.
Humoral immune response induced by an engineered cell-based neuroblastoma vaccine with or without CD25 blockade.
Acta Biochim. Biophys. Sin. (Shanghai). 43: 124-32, 2011.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 3/5/2014.